Many studies have shown that the greater the stirring velocity the smaller the particle size, with greater encapsulation efficiency (Jegat

& Taverdet, 2000; Mascarenhas, 2010, p. 167; Tirkkonen, Turakka, & Paronen, 1994). The particle size distribution followed a unimodal distribution, with a tendency to normality in all the trials. Fig. 3 shows the histograms obtained for a trial at the center point (C18–1.5:1.0 SPI:GA; 2.0:1.0 wall:core; 6.0 UA of TG/g) and for the controls C19 and C20, these being representative of all the trials. In the gas chromatographic analysis of the Doramapimod clinical trial fatty acids, the values for EPA and DHA in the samples after extraction were approximately 55 g/100 g EPA + DHA in the EE. Fig. 4 shows a representative chromatographic profile of all the trials with the main fatty acids identified, with the exception of trial C19, which had no analyzable lipid material in its constitution. It can be seen that the main fatty acids present were EPA, DHA and oleic acid, but can be observed the presence of palmitic acid (C16:0), stearic acid (C18:0), oleic acid (C18:1), stearidonic acid (C18:4), gadoleic acid (C20:1), docosatrienoic acid (C22:3), docosapentanoic find protocol acid (C22:5). According to

Hwang and Liang (2001), fish oil ethyl ester can be constituted of 39–65 g/100 g of EPA and DHA. The analyses of the effects of the concentration of the wall materials (SPI:GA), the wall material to core material ratio (wall:core) and the TG concentration on the amount Sclareol of n-3 EE in the microcapsules, failed to present acceptable regression coefficients (R2 < 70%) for obtaining mathematical models considering the independent variables under study. Table 1 shows

the final values obtained for omega-3 (EPA + DHA) in each trial, and it can be seen that trial C12 (1.5:1.0 SPI:GA; 1.0:1.0 wall:core; 6.0 UA of TG/g) presented approximately 25 g of EPA + DHA in 100 g of microcapsules, followed by trial C14 (1.5:1.0 SPI:GA; 2.0:1.0 wall:core; 10.0 UA of TG/g), with 22.3 g of EPA + DHA in 100 g of microcapsules. Thus based on the National Agency for Sanitary Vigilance (ANVISA – BRASIL, 2009), one would need to add 0.40 g (C12) or 0.45 g (C 14) of microcapsules to 100 g or 100 mL portions of food in order to consider that it had the appeal of a functional property, since the regulation states that foods should present a minimum of 0.1 g EPA and/or DHA per 100 g or 100 mL portion to allow this allegation ( ANVISA, 2009). However, there are numerous recommendations for the daily ingestion of omega-3 fatty acids published by various authors and entities, some of which were listed by Whelan and Rust (2006). According to these authors, in 1999 the British Nutrition Foundation of the United Kingdom recommended the consumption of 1.